Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Xeris Pharmaceuticals Inc (XERS)

Xeris Pharmaceuticals Inc (XERS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 107,502
  • Shares Outstanding, K 37,588
  • Annual Sales, $ 2,720 K
  • Annual Income, $ -125,580 K
  • 60-Month Beta 2.05
  • Price/Sales 40.05
  • Price/Cash Flow N/A
  • Price/Book 4.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.71
  • Number of Estimates 3
  • High Estimate -0.65
  • Low Estimate -0.75
  • Prior Year -1.28
  • Growth Rate Est. (year over year) +44.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.48 +14.11%
on 07/09/20
3.22 -12.11%
on 07/13/20
+0.04 (+1.43%)
since 07/02/20
3-Month
2.28 +24.12%
on 05/04/20
5.92 -52.20%
on 05/26/20
+0.38 (+15.75%)
since 05/01/20
52-Week
1.42 +99.30%
on 03/19/20
12.50 -77.37%
on 08/21/19
-7.92 (-73.67%)
since 08/02/19

Most Recent Stories

More News
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...

XERS : 2.91 (+1.75%)
Xeris Pharmaceuticals Announces Additional Data From a Phase 1b Comparative Study of Its Novel Concentrated Diazepam Formulation (XP-0863) and an Expedited Clinical Path Forward

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...

XERS : 2.91 (+1.75%)
Xeris Pharmaceuticals, Inc. (XERS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

XERS : 2.91 (+1.75%)
Xeris Pharmaceuticals Announces Full Exercise of Underwriters' Options to Purchase Additional Shares and Additional Notes

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...

XERS : 2.91 (+1.75%)
Xeris Pharmaceuticals Announces Gvoke HypoPen(TM) - the First Autoinjector for Severe Hypoglycemia - Now Available

--Approximately 78% of commercially insured and Medicare lives have unrestricted access to Gvoke HypoPen at launch

XERS : 2.91 (+1.75%)
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...

XERS : 2.91 (+1.75%)
Xeris Pharmaceuticals Announces Pricing of Public Offerings of $20 Million of Common Stock and $75 Million of 5.00% Convertible Senior Notes Due 2025

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...

XERS : 2.91 (+1.75%)
Xeris Pharmaceuticals Announces Proposed Public Offerings of $20 Million of Common Stock and $60 Million of Convertible Senior Notes

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...

XERS : 2.91 (+1.75%)
Xeris Pharmaceuticals Announces Positive Topline Results from the Phase 2 Comparative Study of a Novel Pramlintide-insulin Co-formulation (XP-3924) in Adults with Type 1 Diabetes Mellitus

--XP-3924 showed improved glucose control when compared to Humulin(R) R alone

XERS : 2.91 (+1.75%)
Faruqi & Faruqi, LLP is Investigating Xeris Pharmaceuticals, Inc. (XERS) on Behalf of its Shareholders

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential misconduct at Xeris Pharmaceuticals, Inc. ("Xeris" or the "Company") (NASDAQ: XERS).

XERS : 2.91 (+1.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade XERS with:

Business Summary

Xeris Pharmaceuticals, Inc. produces peptides, proteins, antibodies, molecules, auto-injectors, multi-dose pens and infusion pumps to treat endocrine and metabolic diseases. The company's proprietary formulation technologies consist of XeriSol (TM) and XeriJect(TM). Xeris Pharmaceuticals, Inc. is based...

See More

Key Turning Points

2nd Resistance Point 2.96
1st Resistance Point 2.91
Last Price 2.91
1st Support Level 2.77
2nd Support Level 2.68

See More

52-Week High 12.50
Fibonacci 61.8% 8.27
Fibonacci 50% 6.96
Fibonacci 38.2% 5.65
Last Price 2.91
52-Week Low 1.42

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar